https://www.oncologynurseadvisor.com/conferences/american-society-of-clinical-oncology-annual-meeting/ Wed, 03 Jan 2024 19:26:15 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com/conferences/american-society-of-clinical-oncology-annual-meeting/ 32 32 https://www.oncologynurseadvisor.com/reports/asco-2023-breast-cancer-novel-regimens-improved-outcomes-treatment/ Thu, 22 Jun 2023 12:00:00 +0000 https://www.oncologynurseadvisor.com/?p=108805 Presentations at ASCO 2023 focus on improving outcomes for patients with TNBC and HR+/HER2- metastatic breast cancer.]]> https://www.oncologynurseadvisor.com/reports/asco-2023-studies-clarify-role-immunotherapy-multiple-myeloma/ Wed, 21 Jun 2023 13:00:00 +0000 https://www.oncologynurseadvisor.com/?p=108730 Studies from ASCO 2023 revealed new potential standards of care for multiple myeloma and a first for bispecific antibody therapy.]]> https://www.oncologynurseadvisor.com/reports/neoadjuvant-folfirinox-resectable-pancreatic-cancer-does-not-improve-os/ Mon, 05 Jun 2023 14:50:00 +0000 https://www.oncologynurseadvisor.com/?p=108148 Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests. ]]> https://www.oncologynurseadvisor.com/reports/adjuvant-nivolumab-gastric-gej-cancer-no-benefit/ Mon, 05 Jun 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=108156 Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer. ]]> https://www.oncologynurseadvisor.com/reports/telephone-based-wli-successful-in-breast-cancer-survivors/ Fri, 02 Jun 2023 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=108130 Results of the Breast Cancer Weight Loss trial were presented at the 2023 ASCO Annual Meeting. ]]>